STOCK TITAN

Dynavax Technologies Corporation - DVAX STOCK NEWS

Welcome to our dedicated page for Dynavax Technologies Corporation news (Ticker: DVAX), a resource for investors and traders seeking the latest updates and insights on Dynavax Technologies Corporation stock.

Dynavax Technologies Corporation (Nasdaq: DVAX) is a prominent clinical-stage biopharmaceutical firm dedicated to developing innovative vaccines targeting infectious and inflammatory diseases, as well as cancer. With its headquarters in Emeryville, California, the company is renowned for leveraging the body's innate and adaptive immune responses through its proprietary Toll-like Receptor Immune Modulation Platform technology.

Core Products and Clinical Pipeline:

  • HEPLISAV-B®: Approved in the U.S., EU, and Great Britain, HEPLISAV-B is the first and only adult hepatitis B vaccine that allows series completion with just two doses in one month. It continues to show strong market expansion and revenue growth.
  • CpG 1018® Adjuvant: An essential component in multiple adjuvanted COVID-19 vaccines, this adjuvant enhances the immune response.
  • Shingles Vaccine Program (Z-1018): In development for preventing shingles in adults aged 50 and older, promising robust immune responses.
  • Tdap Vaccine Program (Tdap-1018): Focused on active booster immunization against tetanus, diphtheria, and pertussis.
  • Plague Vaccine Program (DV2-PLG-01): In Phase 2 clinical trials, this program is fully funded by the U.S. Department of Defense.

Recent Achievements and Financial Highlights:

  • Dynavax reported record revenue growth for HEPLISAV-B in 2023, capturing significant market share in the adult hepatitis B vaccine sector.
  • As of December 31, 2023, the company had cash, cash equivalents, and marketable securities worth $742.3 million, underpinning its strong financial foundation.
  • For the first quarter of 2024, Dynavax's net loss was reduced compared to the same period in 2023, due to improved operational efficiencies and strategic market initiatives.

Strategic Partnerships:

Collaborations with global biopharmaceutical companies, including AstraZeneca in Europe, further strengthen Dynavax's market position and broaden its product reach.

For detailed financial information and ongoing updates, investors can access the company's Events & Presentations page on their official website.

Rhea-AI Summary
Dynavax Technologies Corporation (DVAX) reports a 69% year-over-year increase in HEPLISAV-B vaccine net product revenue to approximately $213 million for the full year 2023. The company also saw significant gains in HEPLISAV-B market share in the U.S., with total market share increasing to approximately 44% compared to approximately 35% at the end of 2022. Cash, cash equivalents, and marketable securities at year-end increased to approximately $742 million, with the expectation to be cash flow positive for the full year 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.22%
Tags
none
-
Rhea-AI Summary
Dynavax Technologies Corporation (Nasdaq: DVAX) to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.88%
Tags
conferences
-
Rhea-AI Summary
Dynavax Technologies Corporation (DVAX) will present at the 6th Annual Evercore ISI HealthCONx Conference on November 28. The company, a biopharmaceutical firm focusing on innovative vaccines, will webcast the presentation accessible through its Investors website section.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
conferences
Rhea-AI Summary
Dynavax Technologies Corporation (Nasdaq: DVAX) reported Q3 2023 financial results, with HEPLISAV-B vaccine net product revenue of $62.3 million, a 66% YoY increase. They raised their full-year revenue guidance to $210 - $220 million. Cash and investments increased to $720 million. They are focused on advancing their pipeline of innovative vaccine candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.07%
Tags
-
Rhea-AI Summary
Dynavax Technologies Corporation will report its third quarter 2023 financial results on November 2, 2023, after the U.S. financial markets close. The company will host a conference call and live audio webcast on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.56%
Tags
conferences earnings
-
Rhea-AI Summary
Dynavax to present at H.C. Wainwright 4th Annual Hepatitis B Virus Virtual Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
conferences
Rhea-AI Summary
Dynavax Technologies Corporation to participate in fireside chat at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.79%
Tags
conferences
-
Rhea-AI Summary
Dynavax Technologies Corporation reported record quarterly HEPLISAV-B vaccine net product revenue of $56 million, a 73% year-over-year increase. Full year HEPLISAV-B net product revenue guidance was raised to $200 - $215 million. Cash and investments increased to $682 million at quarter end. The company expects positive free cash flow for the full year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.29%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.09%
Tags
conferences earnings
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
conferences

FAQ

What is the current stock price of Dynavax Technologies Corporation (DVAX)?

The current stock price of Dynavax Technologies Corporation (DVAX) is $10.77 as of October 7, 2024.

What is the market cap of Dynavax Technologies Corporation (DVAX)?

The market cap of Dynavax Technologies Corporation (DVAX) is approximately 1.4B.

What is Dynavax Technologies Corporation known for?

Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company specializing in developing vaccines for infectious and inflammatory diseases, and cancer.

What are the key products of Dynavax?

Dynavax's key products include the HEPLISAV-B® hepatitis B vaccine and the CpG 1018® adjuvant used in multiple COVID-19 vaccines.

What is HEPLISAV-B®?

HEPLISAV-B® is an adult hepatitis B vaccine approved in the U.S., EU, and Great Britain, known for enabling series completion with only two doses in one month.

What is the significance of the CpG 1018® adjuvant?

The CpG 1018® adjuvant enhances the immune response in vaccines, including those for COVID-19, shingles, Tdap, and plague.

Who are Dynavax's key partners?

Dynavax collaborates with global biopharmaceutical companies, including AstraZeneca in Europe.

What are the recent financial highlights of Dynavax?

In 2023, Dynavax achieved record revenue growth for HEPLISAV-B and reported substantial cash reserves of $742.3 million as of December 31, 2023.

What is the clinical pipeline focus of Dynavax?

Dynavax's clinical pipeline focuses on differentiated vaccine candidates leveraging the CpG 1018® adjuvant for shingles, Tdap, plague, seasonal influenza, and universal influenza.

How does Dynavax plan to sustain its growth?

Dynavax aims to sustain growth through strategic partnerships, advancing its clinical pipeline, and increasing market share for HEPLISAV-B.

How can investors get updates on Dynavax?

Investors can follow updates on Dynavax through the 'Events & Presentations' page on the company's official website.

What are the most common adverse reactions to HEPLISAV-B?

The most common adverse reactions include injection site pain, fatigue, and headache.

Dynavax Technologies Corporation

Nasdaq:DVAX

DVAX Rankings

DVAX Stock Data

1.41B
130.89M
0.34%
102.48%
13.66%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
EMERYVILLE